1 ***In vitro* evaluation of the activity of terpenes and cannabidiol against**
2 **Human Coronavirus E229**

3

4 Authors - Lior Chatow, Adi Nudel, Iris Nesher, David Hayo Hemo, Perri Rozenberg,
5 Hanna Voropaev, Ilan Winkler, Ronnie Levy, Zohar Kerem, Zohara Yaniv, Nadav Eyal

6

7 Eybna Technologies Ltd., Givat Hen, Israel 43905

8

9 #Corresponding author: Lior Chatow

10 Eybna Technologies Ltd.

11 Pa'amei Aviv 23

12 Givat Hen, 43905 Israel

13 Tel.: +1 888 724 4813

14 Email: info@eybna.com

15

16 **Running title:** Activity of terpenes and cannabidiol against coronavirus

17

18

Abstract

The activity of a new, terpene-based formulation, code-named NT-VRL-1, against Human Coronavirus (HCoV) strain 229E was evaluated in human lung fibroblasts (MRC-5 cells), with and without the addition of cannabidiol (CBD). The tested formulation exhibited an antiviral effect when it was pre-incubated with the host cells prior to virus infection. The combination of NT-VRL-1 with CBD potentiated the antiviral effect better than the positive controls pyrazofurin and glycyrrhizin. There was a strong correlation between the quantitative results from a cell-viability assay and the cytopathic effect seen under the microscope after 72 h. To the best of our knowledge, this is the first report of activity of a combination of terpenes and CBD against a coronavirus.

Keywords: Antiviral; HCoV-229E; Terpenes; CBD; Cannabis; COVID-19

33 Introduction

34 Coronaviruses are enveloped, non-segmented, positive-strand RNA viruses of
35 the family Coronaviridae that cause a wide spectrum of illnesses in humans,
36 including respiratory and gastrointestinal diseases (1). To date, seven human
37 coronaviruses (HCoVs) have been identified. Four of those, HCoV-229E, HCoV-OC43,
38 HCoV-NL63 and HCoV-HKU1, are non-zoonotic and cause worldwide outbreaks of
39 upper respiratory tract infections predominantly in the winter (2). The severe acute
40 respiratory syndrome coronavirus 2 (SARS-CoV-2) has produced an epidemic of
41 Coronavirus Disease 2019 (COVID-19) that started on 31 December 2019 in China
42 and then spread to different regions and countries. According to the WHO (3), as of
43 January 26th, 2021, there have been a total of 98,925,221 confirmed cases of COVID-
44 19 worldwide, including 2,127,294 deaths.

45 This outbreak has led to a search for active antiviral compounds to treat this
46 disease. While SARS-CoV-2 is highly contagious and can only be studied in a biosafety
47 level 4 facility, working with the less virulent strain HCoV-229E is considered a good
48 alternative for preliminary research (2, 4, 5). HCoV-229E is associated with various
49 respiratory illnesses ranging from the common cold to severe pneumonia (6).
50 Recently, the potential of phytochemicals, such as terpenes, for use as potent
51 antiviral agents has received considerable attention, especially because these
52 substances are naturally abundant with relatively low toxicity and cost (7).

53 Terpenes are natural, volatile compounds primarily extracted from plants,
54 which contain only carbon, hydrogen and oxygen atoms. In plants, terpenes act as
55 chemoattractants or chemorepellents (8) and are largely responsible for plant
56 fragrances. In animals and humans, terpenes exhibit a variety of pharmacological

properties, including anti-inflammatory (9), analgesic (10), antimicrobial (11) and antiviral (12) properties. A wide range of *in vitro* studies have demonstrated terpenes' potential for use against a wide range of viruses such as herpes simplex virus (13), bronchitis virus (14), West Nile virus (15) and HIV-1 (16).

As isolated compounds and in plant essential oils, terpenes have been shown to have antiviral effects against several types of HCoVs. Glycyrrhizin, a triterpene found in licorice roots, was one of the first compounds found to be active against SARS coronavirus (SARS-CoV) *in vitro*; it was shown to inhibit SARS-CoV replication with an EC₅₀ of 365 µM (17). Glycyrrhizin has also been used to successfully treat SARS patients (18). *Laurus nobilis* essential oil, with beta-ocimene, 1,8-cineole, alpha-pinene and beta-pinene as its main constituents, was found to exert antiviral activity against SARS-CoV with an IC₅₀ value of 120 mg/mL (19).

Even though the vaccination of the world's population against COVID-19 has begun and is expected to proceed gradually, with no clear expectation of completion. Some individuals will not be vaccinated due to personal choice or health limitations. In addition, several population groups such as younger age groups will be the last to get vaccinated. A natural antiviral solution with minimal side effects that can be used alone or in conjunction with vaccines as a preventative treatment may be a safe and relatively easy way to reduce infection in those populations.

The goal of the present study was to evaluate the antiviral activity of a proprietary terpene formulation (code named NT-VRL-1) against HCoV-229E, with and without the addition of cannabidiol (CBD), and the mode of antiviral action of this formulation during the viral multiplication cycle. The NT-VRL-1 formulation consisted of 30 natural terpenes that are found in cannabis, as well as other plants.

The therapeutic activity of these compounds was evaluated in terms of the cytopathic effect observed under an inverted microscope and an *in vitro* cell viability XTT assay involving human lung fibroblasts (MRC-5 cells) in which the mitochondrial activity of those cells was examined.

Materials and Methods

Materials and reagents

MRC-5 cells and the HCoV-229E strain were purchased from the American Type Culture Collection (ATCC; Manassas, Virginia, United States). All media ingredients and the XTT-based viability assay kit were purchased from Biological Industries (Beit HaEmek, Israel). CBD was purchased from Recipharm Israel (Ness Ziona, Israel). NT-VRL-1 was obtained from Eybna Technologies (Givat Hen, Israel). Glycyrrhizin was obtained from Penta International Corporation (New Jersey, USA) and pyrazofurin was purchased from Sigma (Jerusalem, Israel).

Cytotoxicity of compounds

MRC-5 cells were plated at 1×10^4 cells/well in 96-well plates in minimum essential medium Eagle (EMEM) supplemented with 10% fetal calf serum and then incubated at 37°C with 5% CO₂. The next day, the medium was discarded and 100 µL of EMEM supplemented with 1% fetal calf serum was added to the cells, together with the compounds. The following concentrations were tested for each potential treatment. CBD: 2 µg/mL, 5 µg/mL and 10 µg/mL. NT-VRL-1: 5 µg/mL, 10 µg/mL, 50 µg/mL and 100 µg/mL. NT-VRL-1 + CBD: 10 µg/mL + 1 µg/mL and 10 µg/mL + 3 µg/mL (respectively). Pyrazofurin: 2 µg/mL, 5 µg/mL and 10 µg/mL. Glycyrrhizin: 100

µg/mL, 500 µg/mL and 1000 µg/mL. The cells were incubated for an additional 72 ± 2 h at 34°C and 5% CO₂. Finally, the cells were subjected to an XTT assay. Based on the results of this work, we determined the non-toxic concentrations of the compounds to be used in the efficacy evaluations: CBD (0.5 µg/mL and 1 µg/mL), NT-VRL-1 (2 µg/mL, 5 µg/mL and 10 µg/mL), NT-VRL-1 + CBD (10 µg/mL + 1 µg/mL), pyrazofurin (5 µg/mL) and glycerrihizin (400 µg/mL).

Efficacy of compounds - Cell pretreatment

MRC-5 cells were plated at 1 × 10⁴ cells/well in 96-well plates in EMEM supplemented with 10% fetal calf serum, and then incubated at 37°C and 5% CO₂. The next day, the medium was discarded and 100 µL of EMEM supplemented with 1% fetal calf serum was added to the cells, supplemented with the compounds at concentrations previously identified as nontoxic. The cells were incubated for 1 h at 34°C and 5% CO₂. Next, 1 µL of medium or virus at 100 times the concentration of the infective dose (1:340 dilution) was added to the cells. The cells were incubated for an additional 72 ± 2 h at 34°C and 5% CO₂. Under an inverted microscope, a photograph was taken of the cells in each treatment at 24, 48 and 72 h post-infection. A virus-induced cytopathic effect was observed in comparison with the parallel virus control and cell control. Finally, cells were subjected to an XTT assay.

Efficacy of compounds - Virus pretreatment

MRC-5 cells were plated at 1 × 10⁴ cells/well in 96-well plates in EMEM supplemented with 10% fetal calf serum, and then incubated at 37°C and 5% CO₂. The next day, 120 µL of EMEM supplemented with 1% fetal calf serum was added to

the wells, supplemented with the compounds at concentrations previously identified as nontoxic. The virus was mixed with the compounds in a U-shaped plate and then incubated for 1 h at 34°C and 5% CO₂. Then, 1.2 µL medium or virus at 100 times the concentration of the infective dose was added to the wells. Next, 100 µL of the virus + compounds mixture was added to the cells after medium was removed and the cells were incubated at 34°C and 5% CO₂ for an additional 72 ± 2 h. Under an inverted microscope, photographs of the cells in each treatment were taken at 24, 48 and 72 h post-infection. The virus-induced cytopathic effect was observed in comparison with the parallel virus control and cell control. Finally, cells were subjected to an XTT assay.

Efficacy of compounds – Post-adsorption

MRC-5 cells were plated at 1×10^4 cells/well in 96-well plates in EMEM supplemented with 10% fetal calf serum, and then incubated at 37°C and 5% CO₂. The next day, medium was discarded and EMEM supplemented with 1% fetal calf serum was added to the cells with or without 1 µL of virus at 100 times the concentration of the infective dose. The cells were then incubated for 1 h at 34°C and 5% CO₂. Then, medium was discarded and 100 µL of EMEM supplemented with 1% fetal calf serum was added to the cells, supplemented with the compounds at the concentrations previously identified as nontoxic and 1 µL of media or virus at 100 times the concentration of the infective dose. The cells were incubated for an additional 72 ± 2 h at 34°C and 5% CO₂. Under an inverted microscope, photographs were taken of the cells in each treatment at 24, 48 and 72 h post-infection. The

virus-induced cytopathic effect was observed in comparison with the parallel virus control and cell control. Finally, cells were subjected to an XTT assay.

XTT-based viability assay

At the end of each incubation period, media was discarded from all wells and 100 μ L of fresh culture medium was added to the cells together with 50 μ L of XTT reagent. OD was measured at 450 nm (after subtraction of the non-specific OD at 620 nm).

Results

Cytotoxicity of compounds

The non-cytotoxic concentrations of the various compounds were determined as the concentrations that did not lead to excess cell death, as compared to untreated cells. As shown in **Figure 1**, the non-toxic concentrations were: CBD $\leq$ 1 μ g/mL, NT-VRL-1 $\leq$ 10 μ g/mL, pyrazofurin $\leq$ 10 μ g/mL and glycyrrhizin $\leq$ 500 μ g/mL.

Efficacy of compounds - Cell pretreatment

MRC-5 cells were pretreated with the compounds prior to inoculation with HCoV-229E. As shown in **Figure 2**, the viability of cells that were infected with HCoV-229E, but otherwise untreated, was reduced to ~40% of the viability of the uninfected control cells. Pre-incubation of the cells with all of the compounds prior to virus inoculation rescued the cells and increased the level of cell viability. The combination of 10 μ g/mL NT-VRL-1 with 1 μ g/mL CBD was the most effective treatment associated with the highest level of cell viability ($p < 0.001$). This pattern

was also observed in terms of the cytopathic effect seen under the microscope after 72 h. Swelling and clumping of the MRC-5 cells was observed 72 h after viral infection (**Figure 3**). Cell pretreatment with NT-VRL-1 alone (**Figure 3C**) or NT-VRL-1 + CBD (**Figure 3D**) before viral infection prevented a cytopathic effect.

Efficacy of compounds - Virus pretreatment

HCoV-229E was incubated with the compounds before it was introduced to the MRC-5 cells. As shown in **Figure 4**, inoculation with HCoV-229E (pre-incubation with assay medium) reduced the viability to 80%. Pre-incubation of the virus with 10 µg/mL NT-VRL-1 + 1 µg/mL CBD prior to its introduction to host cells elevated cell viability back to the level observed for the control ($p < 0.001$). In addition, virus pretreatment with NT-VRL-1 + CBD prevented a cytopathic effect after the cells were inoculated with the virus (**Figure 5**)

Efficacy of compounds – Post-adsorption

When the compounds were added to the cells after virus adsorption, the viability of the HCoV-229E-infected cells was reduced to only ~70% of the control, as shown in **Figure 6**. Under these conditions, 10 µg/mL NT-VRL-1 + 1 µg/mL CBD prevented cell death and preserved a level of cell viability similar to that observed for the control ($p < 0.001$). Pyrazofurin at 5 µg/mL also enhanced cell viability ($p < 0.05$) relative to the untreated, infected control. Similar results were observed in terms of the cytopathic effect after 72 h, at which point NT-VRL-1 by itself (**Figure 7C**) and NT-VRL-1 + CBD (**Figure 7D**) both prevented cell damage.

200 Discussion

201 Human coronaviruses have presented a great burden to global health since
202 the 1960's (20). The development of novel, effective antiviral solutions with low
203 toxicity and few side effects is a matter of great interest. Secondary plant
204 metabolites such as terpenes and cannabinoids have been shown to have significant
205 antiviral potential and low toxicity, making them good candidates for use as antiviral
206 agents with minimal side effects (21).

207 With global COVID-19 vaccination in its initial stages, the timeframe for full
208 global vaccination is still unknown. Several population groups, such as the youngest
209 age groups and people with health limitations, will take longer to vaccinate.
210 Therefore, a preventative antiviral treatment to be used in conjunction with vaccines
211 or even temporarily until vaccination or other alternatives become available would
212 be valuable.

213 The objective of this study was to evaluate the anti-viral activity of the NT-
214 VRL-1 terpene formulation, with and without CBD, against human HCoV-229E in
215 human lung fibroblasts *in vitro*. In this study, we report the antiviral activity of the
216 NT-VRL-1 terpene formulation and show that that activity was enhanced when it was
217 applied together with CBD, suggesting either a synergetic or additive effect between
218 the terpene formulation and CBD. Several studies have suggested that
219 phytochemicals found in cannabis may be useful as potential anti-inflammatory
220 agents (22, 23). Such activity may be particularly useful for controlling the cytokine
221 storm syndrome and acute respiratory distress syndrome associated with COVID-19.
222 This study is the first to test cannabis phytochemicals for use against a coronavirus.

Pyrazofurin, a natural antiviral compound that has been shown to be effective against SARS-associated coronaviruses (17), was used as positive control. Glycyrrhizin, which has been shown to have antiviral effect against SARS-associated coronaviruses (24), served as the second positive control.

The mode of antiviral action of NT-VRL-1 was determined by the addition of the compounds to uninfected lung cells, before or after those cells were inoculated with HCoV-229E. The time-of-addition assays can help us to determine the point(s) at which our compound inhibits HCoV-229E replication.

Our results demonstrate that NT-VRL-1's antiviral effect was most pronounced in the pretreatment system, which may indicate that the compounds' antiviral effect is based on the prevention of viral attachment and/or entry. Under these conditions, both CBD (at 0.5–1 µg/mL) and NT-VRL-1 (at 2–10 µg/mL) exhibited observable antiviral effects, as did the positive controls (pyrazofurin at 5 µg/mL and glycyrrhizin at 400 µg/mL). In addition, when CBD (1 µg/mL) and NT-VRL-1 (10 µg/mL) were applied together, we observed a synergistic antiviral effect that was even stronger than that observed for the positive controls.

Terpenes have been shown to have antiviral activity against SARS-CoV (17, 19). However, in previous studies, the terpenes were added to the virus at the same time and no time-of-addition assays were performed. To the best of our knowledge, this is the first report on the antiviral mode of action of terpenes and CBD against a coronavirus.

NT-VRL-1 exhibited an antiviral effect and should preferably be pre-incubated with cells prior to virus exposure. The combination of NT-VRL-1 with CBD amplified this antiviral effect. These results suggest that NT-VRL with or without CBD could be

247 useful as a preventative measure against coronaviruses. As the lungs are the organs
248 most affected by COVID-19, preventative treatment directly to the lungs, possibly via
249 inhalation, would be the ideal administration route for this potential therapeutic
250 solution.

251

252 **Acknowledgments:** We thank Eybna team for their constant encouragement
253 throughout this project. We would like to thank Ina Stelmah and Shlomit Lempert
254 for their supportive efforts and helpful suggestions. We gratefully acknowledge the
255 support of our work and our ideas by our partner Seach Medical Group. Finally, we
256 thank Yaakov Amidror for the valuable discussions related to this work.

References

1. Belouzard S, Millet JK, Licitra BN, Whittaker GR. 2012. Mechanisms of coronavirus cell entry mediated by the viral spike protein. *Viruses* 4:1011–1033.
2. Signer J, Jonsdottir HR, Albrich WC Marc Strasser, Züst R, Ryter S, Ackermann-Gäumann R, Lenz N, Siegrist D, Suter A, Schoop R, Engler. 2020. In vitro virucidal activity of Echinaforce®, an *Echinacea purpurea* preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2. *Virol J* 17:136.
3. World Health Organization Coronavirus Disease (COVID-19) Dashboard (<https://covid19.who.int/>)
4. Ma Q, Li R, Pan W, Huang W, Liu B, Xie Y, Wang Z, Li C, Jiang H, Huang J, Shi Y, Dai J, Zheng K, Li X, Hui M, Fu L, Yang Z. 2020. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway. *Phytomedicine* 78:153296.
5. Parang K, El-Sayed NS, Kazeminy AJ, Tiwari RK. 2020. Comparative antiviral activity of remdesivir and anti-HIV nucleoside analogs against human coronavirus 229E (HCoV-229E). *Molecules* 25(10):2343.
6. Pene F, Merlat A, Vabret A, Rozenberg F, Buzyn A, Dreyfus F, Cariou A, Freymuth F, Lebon P. 2003. Coronavirus 229E-related pneumonia in immunocompromised patients. *Clin Infect Dis* 37(7):929–932.
7. Lillehoj H, Liu Y, Calsamiglia S, Fernandez-Miyakawa ME, Chi F, Cravens RL, Oh S, Gay CG. 2018. Phytochemicals as antibiotic alternatives to promote growth and enhance host health. *Vet Res* 49(1):76.

- 281 8. McGarvey DJ, Croteau R. 1995. Terpenoid metabolism. *Plant Cell* 7:1015–1026.
- 282 9. Prakash V. 2017. Terpenoids as source of anti-inflammatory compounds. *Asian J*
- 283 *Pharm Clin Res* 10:68–76.
- 284 10. Guimarães AG, Quintans JS, Quintans LJ. 2013. Monoterpenes with analgesic
- 285 activity--a systematic review. *Phytother Res* 27(1):1–15.
- 286 11. Guimarães AC, Meireles LM, Lemos MF, Guimarães MCC, Endringer DC, Fronza
- 287 M, Scherer R. 2019. Antibacterial activity of terpenes and terpenoids present
- 288 in essential oils. *Molecules* 24(13):2471.
- 289 12. Astani A, Reichling J, Schnitzler P. 2010. Comparative study on the antiviral
- 290 activity of selected monoterpenes derived from essential oils. *Phytother Res.*
- 291 24(5):673–679.
- 292 13. Astani A, Schnitzler P. 2014. Antiviral activity of monoterpenes beta-pinene and
- 293 limonene against herpes simplex virus in vitro. *Iran J Microbiol* 6(3):149–155.
- 294 14. Yang Z, Wu N, Zu Y, Fu Y. 2011. Comparative anti-infectious bronchitis virus (IBV)
- 295 activity of (-)-pinene: effect on nucleocapsid (N) protein. *Molecules*
- 296 16(2):1044–1054.
- 297 15. Zamora A, Edmonds JH, Reynolds MJ, Khromykh AA, Ralph SJ. 2016. The in vitro
- 298 and in vivo antiviral properties of combined monoterpene alcohols against
- 299 West Nile virus infection. *Virology* 495:18–32.
- 300 16. Bicchi C, Rubiolo P, Ballero M, Sanna C, Matteodo M, Esposito F, Zinzula L,
- 301 Tramontano E. 2009. HIV-1-inhibiting activity of the essential oil of *Ridolfia*
- 302 *segetum* and *Oenanthe crocata*. *Planta Med* 75(12):1331–1335.

- 303 17. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. 2003.
304 Glycyrrhizin, an active component of liquorice roots, and replication of SARS-
305 associated coronavirus. *Lancet* 361(9374):2045–2046.
- 306 18. Haiying L, Na H, Xiaoyuan X. 2003. The curative effects of glycyrrhizin on patients
307 with SARS. Annual Meeting of the Society of Infectious and Parasitic Diseases,
308 Chinese Medical Association, Wuhan, China, Oct. 18–22.
- 309 19. Loizzo MR, Saab AM, Tundis R, Statti GA, Menichini F, Lampronti I, Gambari R,
310 Cinatl J, Doerr HW. 2008. Phytochemical analysis and in vitro antiviral
311 activities of the essential oils of seven Lebanon species. *Chem Biodivers*
312 5(3):461–470.
- 313 20. Tyrrell DA, Bynoe ML. Cultivation of viruses from a high proportion of patients
314 with colds. *Lancet*. 1966 1(7428):76-7.
- 315 21. Biswas D, Nandy S, Mukherjee A, Pandey DK, Dey A. 2020. *Moringa oleifera* Lam
316 and derived phytochemicals as promising antiviral agents: a review. *S Afr J*
317 *Bot* 129:272-282.
- 318 22. Kovalchuk A, Wang B, Li D, Rodriguez-Juarez R, Illynskyy S, Kovalchuk I, Kovalchuk
319 O. 2021. Fighting the storm: could novel anti-TNF α and anti-IL-6 *C. sativa*
320 cultivars tame cytokine storm in COVID-19? *Aging* 13, advance online
321 publication. <https://doi.org/10.18632/aging.202500>.
- 322 23. Anil SM, Shalev N, Vinayaka AC, Nadarajan S, Namdar D, Belausov E, Shoval I,
323 Mani KA, Mechrez G, Koltai H. 2021. Cannabis compounds exhibit anti-
324 inflammatory activity in vitro in COVID-19-related inflammation in lung
325 epithelial cells and pro-inflammatory activity in macrophages. *Sci Rep*
326 11:1462.

327 24. Hoever G, Baltina L, Michaelis M, Kondratenko R, Baltina L, Tolstikov GA, Doerr
328 HW, Cinatl J. 2005. Antiviral activity of glycyrrhizic acid derivatives against
329 SARS coronavirus. J Med Chem 48(4):1256–1259.
330
331

Figure Legends

Figure 1: Cytotoxicity test. MRC-5 cells were treated with different concentrations of the compounds for 72 h. Cell viability was then determined using an XTT assay. Results represent mean percent viability $\pm$ SEM ($n = 4$).

Figure 2: Protective effect of pretreatment of MRC-5 cells with the compounds against HCoV-229E infection. MRC-5 cells were first pretreated with different concentrations of the compounds for 1 h and then exposed to HCoV-229E for an additional 72 h. Cell viability was determined using an XTT assay. Results represent mean percent viability $\pm$ SEM ($n = 4$). Statistics are presented for each treatment compared to cells treated with HCoV-229E only. $*p < 0.05$, $**p < 0.01$ and $***p < 0.001$, according to a t -test.

Figure 3: Effects of pretreatment of MRC-5 cells with terpenes and CBD on the replication and cytopathic effect of HCoV-229E. (A) Healthy MRC-5 cells, (B) MRC-5 cells that had been pretreated with assay medium, photographed 72 h after inoculation with HCoV-229E, (C) MRC-5 cells that had been pretreated with terpenes, photographed 72 h after infection with HCoV-229E, (D) MRC-5 cells that had been pretreated with terpenes and CBD, photographed at 72 h after infection with HCoV-229E.

Figure 4: Effect of pretreatment of HCoV-229E with the compounds on the viability of MRC-5 cells. HCoV-229E was treated with different concentrations of the compounds for 1 h and then incubated with MRC-5 cells for an additional 72 h. Cell

viability was determined using an XTT assay. Results represent mean percent viability $\pm$ SEM ($n = 4$). Statistics are presented for each treatment relative to cells treated with HCoV-229E that had not been pretreated. $*p < 0.05$ and $***p < 0.001$, according to a t -test.

Figure 5: Effect of pretreatment of HCoV-229E with terpenes and CBD on its replication and cytopathic effect in MRC-5 cells. (A) Healthy MRC-5 cells, (B) MRC-5 cells at 72 h after infection with HCoV-229E that had been pretreated with assay medium, (C) MRC-5 cells at 72 h after infection with HCoV-229E that had been pretreated with terpenes and (D) MRC-5 cells at 72 h after infection with HCoV-229E that had been pretreated with terpenes and CBD.

Figure 6: Protective effects of compounds on MRC-5 cells after virus adsorption. HCoV-229E was first added to MRC-5 cells for 1 h. Then, different concentrations of compounds were added to the cells for an additional 72 h. Cell viability was determined using an XTT assay. Results represent mean percent viability $\pm$ SEM ($n = 4$). Statistics are presented for each treatment relative to cells treated only with HCoV-229E. $*p < 0.05$ and $***p < 0.001$, according to a t -test.

Figure 7: Effects of terpenes and CBD applied post-infection on the replication and cytopathic effect of HCoV-229E in MRC-5 cells. (A) Healthy MRC-5 cells, (B) MRC-5 cells at 72 h after infection with HCoV-229E, (C) MRC-5 cells that were pretreated with terpenes, photographed 72 h after infection with HCoV-229E and (D) MRC-5

379 cells that were pretreated with terpenes and CBD, photographed 72 h after infection

380 with HCoV-229E.

381

382

Figure 1:

Cytotoxicity test. MRC-5 cells were treated with different concentrations of the compounds for 72 h. Cell viability was then determined using an XTT assay. Results represent mean percent viability $\pm$ SEM ($n = 4$).

389 **Figure 2:**

390

391 Protective effect of pretreatment of MRC-5 cells with the compounds against HCoV-
 392 229E infection. MRC-5 cells were first pretreated with different concentrations of the
 393 compounds for 1 h and then exposed to HCoV-229E for an additional 72 h. Cell
 394 viability was determined using an XTT assay. Results represent mean percent viability
 395 $\pm$ SEM ($n = 4$). Statistics are presented for each treatment compared to cells treated
 396 with HCoV-229E only. * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$, according to a t -test.

397

398

Figure 3:

Effects of pretreatment of MRC-5 cells with terpenes and CBD on the replication and cytopathic effect of HCoV-229E. (A) Healthy MRC-5 cells, (B) MRC-5 cells that had been pretreated with assay medium, photographed 72 h after inoculation with HCoV-229E, (C) MRC-5 cells that had been pretreated with terpenes, photographed 72 h after infection with HCoV-229E, (D) MRC-5 cells that had been pretreated with terpenes and CBD, photographed at 72 h after infection with HCoV-229E.

Figure 4:

Effect of pretreatment of HCoV-229E with the compounds on the viability of MRC-5 cells. HCoV-229E was treated with different concentrations of the compounds for 1 h and then incubated with MRC-5 cells for an additional 72 h. Cell viability was determined using an XTT assay. Results represent mean percent viability $\pm$ SEM ($n = 4$). Statistics are presented for each treatment relative to cells treated with HCoV-229E that had not been pretreated. * $p < 0.05$ and *** $p < 0.001$, according to a t -test.

Figure 5:

Effect of pretreatment of HCoV-229E with terpenes and CBD on its replication and cytopathic effect in MRC-5 cells. (A) Healthy MRC-5 cells, (B) MRC-5 cells at 72 h after infection with HCoV-229E that had been pretreated with assay medium, (C) MRC-5 cells at 72 h after infection with HCoV-229E that had been pretreated with terpenes and (D) MRC-5 cells at 72 h after infection with HCoV-229E that had been pretreated with terpenes and CBD.

Figure 6:

Protective effects of compounds on MRC-5 cells after virus adsorption. HCoV-229E was first added to MRC-5 cells for 1 h. Then, different concentrations of compounds were added to the cells for an additional 72 h. Cell viability was determined using an XTT assay. Results represent mean percent viability $\pm$ SEM ($n = 4$). Statistics are presented for each treatment relative to cells treated only with HCoV-229E. * $p < 0.05$ and *** $p < 0.001$, according to a t -test.

Figure 7:

Effects of terpenes and CBD applied post-infection on the replication and cytopathic effect of HCoV-229E in MRC-5 cells. (A) Healthy MRC-5 cells, (B) MRC-5 cells at 72 h after infection with HCoV-229E, (C) MRC-5 cells that were pretreated with terpenes, photographed 72 h after infection with HCoV-229E and (D) MRC-5 cells that were pretreated with terpenes and CBD, photographed 72 h after infection with HCoV-229E.